Collaboration Proposal - COVID-19

03. Apr 2020 | 2 min read

Collaboration Proposal - COVID-19

We at Gentian AS believe it is the duty of all companies in the health industry to help combat the ongoing pandemic of COVID-19/Corona virus. High mortality and long hospitalisation are the consequences of the severe cases with COVID-19 pneumonia. Hence, it is important to identify biomarkers that early could aid in rapid and effective identification of the severely affected patients. In the Gentian test portfolio, the two biomarkers, cystatin C and plasma calprotectin, could be useful for the early detection of the severely affected COVID-19 patients. To do our part we are reaching out to research/hospital institutions who want to run a trial to assess whether these biomarkers can make a contribution in the detection of severe COVID-19 cases.

Plasma calprotectin (GCAL®*)as been shown as a promising biomarker in differentiation between bacterial and viral infections [1, 2] and as a useful biomarker for prediction of severe events, including mortality in septic patients [3]. In COVID-19 patients, an early biomarker of neutrophil activation such as calprotectin [4, 5] could be used to early identify patients with bacterial coinfections and patients at risk to develop severe events.

Also, cystatin C providing an accurate estimate of the glomerular filtration function can further help to identify the serious cases amongst patients infected with COVID-19 since renal failure is a frequent complication of acute respiratory distress syndrome as indicated by Dr. Hendrickson et al [unpublished results] and also revealed in COVID-19 patients as indicated by Dr. Xiang and Dr. Wen [unpublished results].

We believe that performing cystatin C and plasma calprotectin tests in parallel on the COVID-19 patients could provide additional information for the treating health care professional and we encourage interested researchers to reach out to us at research@gentian.com. We will simultaneously use our network to actively look for study partners, so that this research can be started as soon as possible.

References:

  1. Havelka et al., Sci Rep. 2020 Mar 6;10(1):4208
  2. Bartáková et al., Diagn Microbiol Infect Dis. 2019 Mar;93(3):219-226
  3. Larsson et al. Scand J Clin Lab Invest. 2020 Feb - Apr;80(2):156-161
  4. Jonsson et al., Crit Care Resusc. 2017 Sep;19(3):205-213
  5. Lipcsey et al., Innate Immun. 2019 Aug;25(6):369-373

*In US, for research use only

You may also read


What type of antibodies are used in Gentian’s Cystatin C Immunoassay?

May 20, 2020

What type of antibodies are used in Gentian’s Cystatin C Immunoassay?

In this segment we will answer questions our Product Manager for cystatin C and Product Specialist in the US..

Gentian Insight: PETIA

May 06, 2020

Gentian Insight: PETIA

Gentian’s proprietary antibody and nanoparticle-based technology supports development of highly sensitive..

Webinar: Why choose Gentian Cystatin C Immunoassay

Apr 30, 2020

Webinar: Why choose Gentian Cystatin C Immunoassay

Want to know more about Gentian’s cystatin C immunoassay? Watch this webinar with Gentian’s Product Manager..